Welcome & Introduction

SURGICAL OUTCOMES FROM THE PHASE 3 CHECKMATE 816 TRIAL

Neoadjuvant Pembrolizumab for Early Stage Non Small Cell Lung Cancer

LONG TERM SURVIVAL data presented in WCLC Sept 2021

OUTCOMES OF ANTI PD THERAPY IN COMBINATION WITH CHEMOTHERAPY VS IMMUNOTHERAPY ALONE FOR FIRST-LINE

Atezolizumab in the management of 1L mNSCLC IMPower 150

Five Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic

IO + IO Combinations in 1st Line Treatment of Stage IV NSCLC

Early circulating tumour DNA for predicting & monitoring response

Discussion on abstracts of clinical practice

Panel Discussion - IO in 1st line PF L1 negative advanced NSCLC

Should we recommend IO First Line in PDL1 Negative patients Advanced NSCLC

Role of Dual I-O therapy in treatment of 1L mNSCLC

Evolving role of Immunotherapy in ES SCLC

Closing Remarks